Cyclopharm (ASX:CYC) announced a multi-site agreement with the prestigious University of Pennsylvania Health System.
The deal encompasses 11 clinical locations across Pennsylvania and New Jersey, marking a high-profile "lighthouse win" for the company in the competitive Philadelphia medical market.
Under the three-year contract, Cyclopharm will immediately commence two Technegas installations at the Hospital of the University of Pennsylvania and the Perelman Centre for Advanced Medicine, with plans to roll out across an additional nine network sites over the coming months.
This partnership is a key driver for Cyclopharm's US rollout, establishing critical regional density within the Mid-Atlantic corridor.
Beyond the initial hardware setup, the agreement secures a robust recurring revenue profile through annual service fees and the sale of per-patient consumables.
As the Hospital of the University of Pennsylvania is currently ranked as a top 20 facility in the United States, this collaboration serves as a powerful endorsement of Technegas technology within a premier academic health system.
Management anticipates that this foundational agreement will provide a clear pathway for further expansion into affiliated networks and the broader Northeast region.
At the time of reporting, Cyclopharm's share price was $0.73.